Abstract Details

Title Phase 1 Studies of the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous PEGylated Interferon-Beta in Healthy Volunteers

Topic MS and Related Diseases

Presentation(s) (-)

Poster/Presentation
Number 122

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Kenneth Grabstein, PhD (Allozyne, Inc.)	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Daniel Burge, MD	No disclosure on file
Bernard M. Uitdehaag, MD, PhD, FAAN (Amsterdam University Medical Centers)	Dr. Uitdehaag has nothing to disclose.

��ɫ��